Symptomatic inflammatory musculoskeletal pain where etoricoxib 90 mg is locally approved for the specific indication.
Selective COX-2 inhibition reduces prostaglandin synthesis and inflammation.
Higher strengths are not simply 'better'; dose should match the approved indication.
Cardiovascular and blood-pressure risks remain dose/exposure considerations.
Composition & dosage
Composition: Etoricoxib · 90 mg
Dosage form: Tablet
Dosage: As prescribed by the doctor.
How it works
Selective COX-2 inhibition reduces prostaglandin generation associated with pain and inflammation.
Selective COX-2 inhibition reduces prostaglandin generation associated with pain and inflammation.
Etoricoxib has substantial randomized and network meta-analysis evidence for pain and function in osteoarthritis and other inflammatory pain contexts.
Safety information
Avoid in uncontrolled hypertension and relevant cardiovascular disease according to local labeling.
Assess renal function, fluid retention and GI risk.
Use the lowest effective dose for the shortest appropriate duration.
Review the current approved prescribing information, contraindications, interactions, organ-function considerations, pregnancy/lactation advice and patient-specific risks before prescribing.
Evidence context
Etoricoxib has substantial randomized and network meta-analysis evidence for pain and function in osteoarthritis and other inflammatory pain contexts.
Cardiovascular, blood-pressure, renal and GI risk remain central; higher analgesic ranking is not equivalent to best choice for every patient.